Discovery of Natural Phosphodiesterase 5 Inhibitors from Dalbergia cochinchinensis Pierre Leaves Using LC-QTOF-MS2 [0.03%]
Ruttanaporn Chantakul,Corine Girard,François Senejoux et al.
Ruttanaporn Chantakul et al.
The imbalance of phosphodiesterase 5 (PDE5) enzyme in the male body, or excessive PDE5 enzyme levels, can occur due to factors such as aging, diseases (e.g., cardiovascular disease, diabetes, depressive disorder), and physical behaviors (e....
Anna I Malykhina,Svetlana S Efimova,Olga S Ostroumova
Anna I Malykhina
Background/Objectives: Phosphodiesterase 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, activate the cyclic guanosine monophosphate pathway resulting in vascular smooth muscle relaxation. They have been tested for a broad varie...
Treatment With Phosphodiesterase 5 Inhibitors and Long-Term Outcomes in Patients Undergoing Coronary Angiography and Cardiac Catheterization [0.03%]
磷酸二酯酶5抑制剂治疗与冠状动脉造影和心导管检查患者的长期预后关系的研究
Sumon Roy,Annette Min,Edward O McFalls et al.
Sumon Roy et al.
Background: The effects of phosphodiesterase 5 (PDE5) inhibitors on the incidence of long-term outcomes in patients with cardiovascular disease are not well understood. ...
Prognosis and Treatment With Phosphodiesterase 5 Inhibitors in Combined Post- and Precapillary Pulmonary Hypertension: A Propensity Score-Matched Analysis From the Hellenic Pulmonary Hypertension Registry [0.03%]
结合肺动脉高压的预后和磷酸二酯酶5抑制剂治疗：来自希腊肺动脉高压登记处的倾向性评分匹配分析
Georgios E Papadopoulos,Alexandra Arvanitaki,Sophia-Anastasia Mouratoglou et al.
Georgios E Papadopoulos et al.
This study examines the impact of PVR > 5 WU on survival in heart failure with preserved ejection fraction (HFpEF) and CpcPH and evaluates the effect of treatment with phosphodiesterase 5 inhibitors (PDE5is) on clinical and hemodynamic parameters and on prognosis.
Meta-analysis of targeted drugs for pulmonary hypertension to improve exercise tolerance and associated factors in eisenmenger syndrome [0.03%]
靶向药物治疗艾森曼格综合征肺动脉高压改善运动耐量和相关因素的 meta 分析
Zhangli Yuan,Yang Wang,Jianling Wang et al.
Zhangli Yuan et al.
Results: A total of 393 patients with ES were included in 13 papers, including 8 studies of endothelin receptor antagonists (ERA), 2 studies of phosphodiesterase 5 inhibitors (PDE5i) and 3 studies of prostanoids.
Exogenous administration of heparin-binding epidermal growth factor-like growth factor improves erectile function in mice with bilateral cavernous nerve injury [0.03%]
外源性肝素结合表皮生长因子样生长因子可改善双侧阴茎海绵体神经损伤小鼠的勃起功能
Minh Nhat Vo,Mi-Hye Kwon,Fang-Yuan Liu et al.
Minh Nhat Vo et al.
The poor efficacy of phosphodiesterase 5 inhibitors after surgery highlights the need to develop new therapies to enhance cavernous nerve regeneration and improve the erectile function of these patients.
Treatment Patterns of Patients With Pulmonary Hypertension: A Descriptive Study in Colombia [0.03%]
肺动脉高压患者的治疗模式：来自哥伦比亚的描述性研究
Manuel Machado-Duque,Andrés Gaviria-Mendoza,Luis Fernando Valladales-Restrepo et al.
Manuel Machado-Duque et al.
The most frequently used drugs for the treatment of PH were calcium channel blockers (58.1%), followed by phosphodiesterase 5 inhibitors (41.1%), endothelin receptor antagonist (32.5%), and guanylate cyclase stimulants (9.7%).
Tieqiang Zong,Xing Huang,Wei Zhou et al.
Tieqiang Zong et al.
Phosphodiesterase 5 (PDE5) can hydrolyze cyclic guanosine monophosphate (cGMP), which is critical for maintaining various physiological processes in organisms. Currently, clinically approved indications for PDE5 inhibitors encompass therape...
Molecular Dynamics-Assisted Discovery of Novel Phosphodiesterase-5 Inhibitors Targeting a Unique Allosteric Pocket [0.03%]
基于分子动力学的新型磷酸二酯酶-5 allosteric抑制剂的研究与发展
Weihao Luo,Runduo Liu,Xinlin Cai et al.
Weihao Luo et al.
Phosphodiesterase-5 (PDE5) is a potent therapeutic target for the treatment of male erectile dysfunction and pulmonary arterial hypertension with several drugs available on the market. However, most of the reported PDE5 inhibitors lack spec...
Treatment pathways in Finnish patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) [0.03%]
芬兰肺动脉高压（PAH）或慢性血栓栓塞性肺高血压（CTEPH）患者的治疗路径
Markku Pentikäinen,Piia Simonen,Pauliina Leskelä et al.
Markku Pentikäinen et al.
PAH treatment at 1 year after diagnosis included phosphodiesterase 5 inhibitors (71%), endothelin-receptor antagonist (48%), prostacyclin analogue (7%), calcium channel blocker (12%) and selexipag (1%). 35% achieved low risk at 1 year, increasing to 44% for patients diagnosed after 2015.
耗时 0.13626 秒，为您在
48223910
条记录里面共找到 515 篇文章 [XML]